[333 Pages Report] The global ocular tuberculosis therapeutics market is forecasted to be valued at US$ 753.2 million by 2032, up from US$ 405.0 million in 2022 and is advancing at a CAGR of 5.8% during the forecast period.
| Report Attribute | Details |
|---|---|
| Ocular Tuberculosis Therapeutics Market Value (2022) | US$ 405.0 Million |
| Ocular Tuberculosis Therapeutics Market Anticipated Value (2032) | US$ 753.2 Million |
| Ocular Tuberculosis Therapeutics Projected Growth Rate (2022 to 2032) | 5.8% |
It is identified that ocular tuberculosis is a rare form of tuberculosis that infects various parts of an eye including the lid, cornea, or the surrounding areas. According to the data of WHO, tuberculosis is one of the top ten landing causes of death in the world. Therefore, to minimize the death rate and the number of people affected by ocular tuberculosis, the ocular tuberculosis therapeutics market size is on the rise.
The demand for ocular tuberculosis therapeutics is increasing as there are a large number of cases of secondary ocular tuberculosis due to hematogenous spread from distant sites or by direct invasions from adjacent structures like the cranial cavity or sinus.
Therefore, it is anticipated that the population suffering from ocular tuberculosis are resorting to ocular tuberculosis therapeutics and the market is likely to witness significant growth during the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
When given in the correct dosage, the various combination of drugs leads to the prevention of incidence of ocular tuberculosis, curing the disease. This factor is driving the market for ocular tuberculosis therapeutics.
Moreover, the growth of the ocular tuberculosis therapeutics market can be attributed to the rising demand for improved therapeutics that can treat tuberculosis, including ocular tuberculosis.
Furthermore, combination therapy in the ocular tuberculosis therapeutics market is being highly adopted because of the growing prevalence of multi-drug resistant tuberculosis.
In addition to this, the first-line drugs lie Rifampicin, Ethambutol, Isoniazid, and Pyrazinamide, which are being used at the initial stage of tuberculosis and are having high demand in the therapeutics market. Some second-line drugs in high demand are Fluoroquinolones, Cycloserine, Thioamides, and others. It is anticipated that the demand for these drugs is a key driving factor in the ocular tuberculosis therapeutics market and is likely to boost the demand for the product during the forecast period.
Furthermore, it is projected that the increased funding I clinical research and healthcare by both public and private institutions, along with government organizations, is a major factor leading to the expansion of the ocular tuberculosis therapeutics market.
It is anticipated that there is a lack of medical check-up protocol, which is expected to hinder the growth of the ocular tuberculosis therapeutics market over the upcoming years.
Furthermore, ocular tuberculosis is a very rare condition and is currently undergoing study and research. In regards to this, there is very limited availability of necessary therapeutics or other drugs for the treatment of tuberculosis in the eye. This factor is estimated to curb the growth of the ocular tuberculosis therapeutics market.
Principal Consultant
North America is projected to hold the largest market share of the ocular tuberculosis therapeutics market. It is currently accountable for 36.0% of the total market share for the ocular tuberculosis therapeutics market.
This expansion and growth in the North American regions can be attributed to the increasing number of developments in the healthcare industry.
It is also anticipated that the North American region has a growing demand for better and advanced tuberculosis therapies, which is driving the expansion of the market size of the ocular tuberculosis therapeutics market.
The European region has a potential growth outlook for the ocular tuberculosis therapeutics market. It is currently accountable for 27.9% of the total market share of the ocular tuberculosis therapeutics market.
The growing demand for ocular tuberculosis therapeutics in this region is due to the increasing population of this region, coupled with rising disposable income, which is driving the populace to undergo therapies that cure ocular tuberculosis faster.
In addition to that, there are research grants offered by various organizations in this region in ocular tuberculosis therapeutics to bring in more product developments.
The start-up ecosystem in the ocular tuberculosis therapeutics market is intense with frequent innovations being made. Start-ups in the ocular tuberculosis therapeutics market are focusing on improvising the therapeutics for faster cure delivery to the patients.
Indian start-up Everwell has developed HealthTech technologies for patient adherence. The start-up’s digital adherence technology, 99DOTS, uses low-cost packaging with hidden codes to encourage patients to take their medications daily. It requires the patient to register daily adherence by communicating the hidden code via a toll-free call, SMS, or other channels.
Quartis, is a South Korean startup developing a novel TB vaccine. The start-up’s subunit vaccine, QTP101, target multiple antigens associated with virulence and latency.
Swedish start-up Astrego offers in-vitro diagnostics solutions to tackle antimicrobial resistance. The start-up’s PA-100 system uses a desktop instrument and specific panels for rapid screening. The auto-mated solution provides personalized antibiotic prescriptions for tuberculosis, as well as urinary tract infections, respiratory conditions, and sepsis.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some of the ocular tuberculosis therapeutics market participants are AstraZeneca, Bayer HealthCare AG, Biological E, BioVersys, Cadila Pharmaceuticals, Concept Pharmaceuticals Ltd., Infectex, Johnson & Johnson, Labatec-Pharma SA, Lupin Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Maneesh Pharmaceuticals, Novartis, Otsuka Novel Products, Pfizer, Pharmasyntez, Sandoz, Sanofi, Sequella, Inc., and Themis Medicare Ltd.
The key players in the market are involving themselves in the development of improvised therapeutics. They are receiving raised initiatives by the government for the promotion of research and development activities for bringing advanced solutions for ocular tuberculosis and fast-cure range of therapeutics in the global ocular tuberculosis therapeutics market
Some key developments in the ocular tuberculosis therapeutics market are:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5.8% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2016 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The ocular tuberculosis therapeutics market is predicted to advance at a CAGR of 5.8% from 2022 to 2032.
The North American region is anticipated to lead the ocular tuberculosis therapeutics market during the forecast period.
The ocular tuberculosis therapeutics market is likely to hold a valuation of US$ 753.2 million by 2032.
The healthcare and hospital sector are the key contributors to the ocular tuberculosis therapeutics market.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Treatment, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Treatment, 2022-2032
5.3.1. First line treatment
5.3.1.1. Rifampicin
5.3.1.2. Isoniazide
5.3.1.3. Ethambutol
5.3.1.4. Pyrazinamide
5.3.2. Second line treatment
5.3.2.1. Flouroquinolones
5.3.2.2. Aminoglycosides
5.3.2.3. Cycloserine
5.3.2.4. Polypeptides
5.3.2.5. p-Aminosalicylic Acid
5.3.2.6. Thioamides
5.3.3. Combination Therapy
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2017-2021
5.5. Absolute $ Opportunity Analysis By Treatment, 2022-2032
6. Global Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By end-user
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By end-user, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By end-user, 2022-2032
6.3.1. Hospital
6.3.2. Clinics
6.3.3. Ambulatory Surgical Centers
6.4. Y-o-Y Growth Trend Analysis By end-user, 2017-2021
6.5. Absolute $ Opportunity Analysis By end-user, 2022-2032
7. Global Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Treatment
8.2.3. By end-user
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment
8.3.3. By end-user
8.4. Key Takeaways
9. Latin America Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment
9.2.3. By end-user
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By end-user
9.4. Key Takeaways
10. Europe Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. U.K.
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment
10.2.3. By end-user
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By end-user
10.4. Key Takeaways
11. Asia Pacific Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Malaysia
11.2.1.5. Singapore
11.2.1.6. Australia
11.2.1.7. New Zealand
11.2.1.8. Rest of APAC
11.2.2. By Treatment
11.2.3. By end-user
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By end-user
11.4. Key Takeaways
12. MEA Ocular Tuberculosis Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Treatment
12.2.3. By end-user
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By end-user
12.4. Key Takeaways
13. Key Countries Ocular Tuberculosis Therapeutics Market Analysis
13.1. U.S.
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2021
13.1.2.1. By Treatment
13.1.2.2. By end-user
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2021
13.2.2.1. By Treatment
13.2.2.2. By end-user
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2021
13.3.2.1. By Treatment
13.3.2.2. By end-user
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2021
13.4.2.1. By Treatment
13.4.2.2. By end-user
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2021
13.5.2.1. By Treatment
13.5.2.2. By end-user
13.6. U.K.
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2021
13.6.2.1. By Treatment
13.6.2.2. By end-user
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2021
13.7.2.1. By Treatment
13.7.2.2. By end-user
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2021
13.8.2.1. By Treatment
13.8.2.2. By end-user
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2021
13.9.2.1. By Treatment
13.9.2.2. By end-user
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2021
13.10.2.1. By Treatment
13.10.2.2. By end-user
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2021
13.11.2.1. By Treatment
13.11.2.2. By end-user
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2021
13.12.2.1. By Treatment
13.12.2.2. By end-user
13.13. Malaysia
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2021
13.13.2.1. By Treatment
13.13.2.2. By end-user
13.14. Singapore
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2021
13.14.2.1. By Treatment
13.14.2.2. By end-user
13.15. Australia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2021
13.15.2.1. By Treatment
13.15.2.2. By end-user
13.16. New Zealand
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2021
13.16.2.1. By Treatment
13.16.2.2. By end-user
13.17. GCC Countries
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2021
13.17.2.1. By Treatment
13.17.2.2. By end-user
13.18. South Africa
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2021
13.18.2.1. By Treatment
13.18.2.2. By end-user
13.19. Israel
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2021
13.19.2.1. By Treatment
13.19.2.2. By end-user
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Treatment
14.3.3. By end-user
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. AstraZeneca
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Bayer HealthCare AG
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Biological E
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. BioVersys
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Cadila Pharmaceuticals
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Concept Pharmaceuticals Ltd.
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Infectex, Johnson & Johnson
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Labatec-Pharma SA
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Lupin Pharmaceuticals Inc.
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Macleods Pharmaceuticals Ltd.
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
15.1.11. Maneesh Pharmaceuticals
15.1.11.1. Overview
15.1.11.2. Product Portfolio
15.1.11.3. Profitability by Market Segments
15.1.11.4. Sales Footprint
15.1.11.5. Strategy Overview
15.1.11.5.1. Marketing Strategy
15.1.12. Novartis
15.1.12.1. Overview
15.1.12.2. Product Portfolio
15.1.12.3. Profitability by Market Segments
15.1.12.4. Sales Footprint
15.1.12.5. Strategy Overview
15.1.12.5.1. Marketing Strategy
15.1.13. Otsuka Novel Products
15.1.13.1. Overview
15.1.13.2. Product Portfolio
15.1.13.3. Profitability by Market Segments
15.1.13.4. Sales Footprint
15.1.13.5. Strategy Overview
15.1.13.5.1. Marketing Strategy
15.1.14. Pfizer
15.1.14.1. Overview
15.1.14.2. Product Portfolio
15.1.14.3. Profitability by Market Segments
15.1.14.4. Sales Footprint
15.1.14.5. Strategy Overview
15.1.14.5.1. Marketing Strategy
15.1.15. Pharmasyntez
15.1.15.1. Overview
15.1.15.2. Product Portfolio
15.1.15.3. Profitability by Market Segments
15.1.15.4. Sales Footprint
15.1.15.5. Strategy Overview
15.1.15.5.1. Marketing Strategy
15.1.16. Sandoz
15.1.16.1. Overview
15.1.16.2. Product Portfolio
15.1.16.3. Profitability by Market Segments
15.1.16.4. Sales Footprint
15.1.16.5. Strategy Overview
15.1.16.5.1. Marketing Strategy
15.1.17. Sanofi
15.1.17.1. Overview
15.1.17.2. Product Portfolio
15.1.17.3. Profitability by Market Segments
15.1.17.4. Sales Footprint
15.1.17.5. Strategy Overview
15.1.17.5.1. Marketing Strategy
15.1.18. Sequella, Inc.
15.1.18.1. Overview
15.1.18.2. Product Portfolio
15.1.18.3. Profitability by Market Segments
15.1.18.4. Sales Footprint
15.1.18.5. Strategy Overview
15.1.18.5.1. Marketing Strategy
15.1.19. Themis Medicare Ltd.
15.1.19.1. Overview
15.1.19.2. Product Portfolio
15.1.19.3. Profitability by Market Segments
15.1.19.4. Sales Footprint
15.1.19.5. Strategy Overview
15.1.19.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Explore Healthcare Insights
View Reports
Ocular Tuberculosis Therapeutics Market
